Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IONIS FXI-LRx · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IONIS FXI-LRx | EXPERIMENTAL | Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection. |
| Placebo | PLACEBO_COMPARATOR | Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator. |
| Name | Type | Description |
|---|---|---|
| IONIS FXI-LRx | DRUG | Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection |
| Placebo | DRUG | Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator |
Inclusion Criteria * Body mass index (BMI) ≤ 35 kg/m2 * Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal * Males must be surgically sterile, abstinent or, if engaged in sexual relations with a female of child-bearing potential, the subject must be usi...
IONIS FXI-LRx is an investigational drug being studied in healthy participants. It is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics in a clinical trial. The drug is in Phase 1 development and is not yet approved for any medical use.
IONIS FXI-LRx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical research to assess the drug's properties in healthy volunteers.
IONIS FXI-LRx is in Phase 1 clinical development. A Phase 1 trial has been completed to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants. The drug remains investigational and has not been approved by regulatory authorities.
IONIS FXI-LRx has been studied in one clinical trial with the identifier NCT03582462. This completed Phase 1 study assessed single and multiple doses of the drug in up to 84 healthy volunteers in Canada. The trial enrolled 66 participants and was placebo-controlled and double-blind.
IONIS FXI-LRx is the drug name used in the clinical trial record. The trial title refers to the drug as IONIS FXI-LRx, and no other alternative names have been reported. The drug is being developed by Ionis Pharmaceuticals under this designation.